In the future, we will further dig deeper into the mechanism of action of MEnZn‐CuO NPs and find the key proteins affecting the combination of MEnZn‐CuO NPs and PARP inhibitors, which will open up a new avenue for the treatment of ovarian cancer. This evidence concerns the gene PARP1 and ovarian cancer.